Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Oncotarget. 2015. PMID: 26056084 Free PMC article.
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.
Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A. Ocio EM, et al. Blood. 2009 Apr 16;113(16):3781-91. doi: 10.1182/blood-2008-09-177774. Epub 2008 Nov 19. Blood. 2009. PMID: 19020308 Free article.
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San-Miguel JF. Ocio EM, et al. Haematologica. 2010 May;95(5):794-803. doi: 10.3324/haematol.2009.015495. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951978 Free PMC article.
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF. Colado E, et al. Haematologica. 2011 May;96(5):687-95. doi: 10.3324/haematol.2010.036400. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330323 Free PMC article.
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, García-Macías MDC, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E. Ordóñez JL, et al. Oncotarget. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610. Oncotarget. 2017. PMID: 28672777 Free PMC article. No abstract available.
C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.
Martín-Granado V, Ortiz-Rivero S, Carmona R, Gutiérrez-Herrero S, Barrera M, San-Segundo L, Sequera C, Perdiguero P, Lozano F, Martín-Herrero F, González-Porras JR, Muñoz-Chápuli R, Porras A, Guerrero C. Martín-Granado V, et al. Oncotarget. 2017 Nov 6;8(67):110994-111011. doi: 10.18632/oncotarget.22339. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340032 Free PMC article.
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M, Hernández-Sánchez M, Alonso-Pérez V, Rodríguez-Vicente AE, García-Tuñón I, Martín-Izquierdo M, Hernández-Sánchez JM, Herrero AB, Bastida JM, San Segundo L, Gruber M, García JL, Yin S, Ten Hacken E, Benito R, Ordóñez JL, Wu CJ, Hernández-Rivas JM. Quijada-Álamo M, et al. Among authors: san segundo l. Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23. Leukemia. 2020. PMID: 31974435 Free PMC article.
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T, Garcia-Gomez A, González-Méndez L, San-Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho D, Ortiz-de-Solorzano C, Corchete LA, Gutiérrez NC, Maetos MV, Garayoa M, Ocio EM. Paíno T, et al. Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20. Clin Cancer Res. 2017. PMID: 27440267
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Hernández-García S, San-Segundo L, González-Méndez L, Corchete LA, Misiewicz-Krzeminska I, Martín-Sánchez M, López-Iglesias AA, Algarín EM, Mogollón P, Díaz-Tejedor A, Paíno T, Tunquist B, Mateos MV, Gutiérrez NC, Díaz-Rodriguez E, Garayoa M, Ocio EM. Hernández-García S, et al. Haematologica. 2017 Dec;102(12):2113-2124. doi: 10.3324/haematol.2017.168666. Epub 2017 Aug 31. Haematologica. 2017. PMID: 28860344 Free PMC article.
40 results